Takeda pledges support to HAE patients through its ‘Sunrise patient support program’
· Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
· Availability of a toll-free help line number 1800 103 4260 to provide coordination & counselling support for patients
· The initiative aims to drive HAE awareness through patient education, and timely diagnosis through free of cost diagnostics as the key growth drivers to address priority unmet needs
Mumbai, 10th May 2023: Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Pvt. Ltd.), a global values-based, R&D-driven biopharmaceutical leader has launched its ‘Sunrise Patient Services Program (PSP)’ for Hereditary Angioedema (HAE) patients in India.
HAE is a life-threatening rare genetic disease that affects various parts of the body, such as limbs, hands, feet, genitals, abdomen face, and throat. In addition, patients often have bouts of excruciating abdominal pain, nausea and vomiting that is caused by swelling in the intestinal wall. Airway swelling is particularly dangerous and can lead to death by asphyxiation. [i]
What is Sunrise PSP?
Sunrise is a patient support program and as the name suggests, the goal is for the sun to rise on a new dawn bringing hope to HAE patients in India. It is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support implemented by an independent patient services agency funded by Takeda. Highlights of the program include:
· Field counselling and tele-support services
· Free of cost HAE testing through quality diagnostic labs
· Treatment reimbursement navigation and lifestyle counselling support throughout the patient’s treatment journey
Speaking about the Sunrise PSP launch, Dr. Sandeep Arora, Head, of Medical Affairs and Patient Services, said, “HAE is a lifelong disorder, and we at Takeda are highly committed to supporting patients fighting HAE among other rare diseases. This disease is grossly under recognized in India because of lack of awareness and diagnostic facilities. As per reports, approximately 50% [ii]of HAE patients receive more than one misdiagnosis in their lifetimes. Additionally, 50% of patients experience a delay of over 10 years from the onset of symptoms to the correct diagnosis.[iii] Due to lack of epidemiological data in India, early diagnosis is often not carried out and patients continue suffering for the entirety of their li ves. With the introduction of Sunrise PSP, we hope to positively impact the quality of life for HAE patients in India.”
The program launched by Takeda strives to advance healthcare standards and enhance the quality of life in the world of HAE where awareness is limited leading to preventable morbidity and mortality. The company intends to create a positive impact on patients' lives by increasing awareness of HAE and access to free of cost diagnostics & empowering HAE patients to access their treatments with ease and manage their lifestyle comfortably to lead fulfilling and meaningful lives.
The patient-service program has also set up a toll-free helpline number to provide adequate counselling, which will further help in tracking the patient’s symptoms and prompt diagnosis for better health outcomes and improved lifestyle.
What is HAE?
As per the statistics, Hereditary Angioedema (HAE) affects approximately 1 in 50,000[iv] people worldwide. In India, HAE grossly remains under-recognized and misdiagnosed. Significant time patients experience a high delay from the onset of symptoms impacting the treatment process.[v]
HAE can be life-threatening in severe cases, especially when it attacks the larynx (voice box) or trachea (windpipe). In such circumstances, it requires a medical emergency and should not be neglected at any cost. It is found that 29 percent[vi] of mortality is due to asphyxiation from laryngeal attacks in undiagnosed patients, while 3 percent[vii] is in patients diagnosed with HAE. Therefore, it is imperative to aware people of HAE and its early diagnosis so that effective treatment can be initiated and enables not just in reducing the mortality rate but also improves the quality of life for patients.
HAE is often misdiagnosed as allergic/ non-allergic angioedema, peptic ulcers, etc which could directly impact patient’s overall well-being. As per reports, it is observed that:
· Every one in five HAE patients also undergoes unnecessary surgeries such as appendectomies[viii]
· 20-25% of HAE cases are new mutations with no family history[ix]
· 50% of patients will have 31 laryngeal attack in their lifetime[x]
· The lifespan of individuals with undiagnosed HAE who die from laryngeal attacks is on average 31 years shorter than 4 undiagnosed patients who die from other causes[xi]
Hence, it becomes extremely critical to invest in innovative therapies and enhances awareness of this rare condition.
Reach out to Sunrise through:
Toll free number: 1800 103 4260
Website: https://www.knowhae.in/
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit https://www.takeda.com.
Important Notice
For the purposes of this notice, "press release" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together wi th any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could” "anticipates", "estimates", "projects" or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda's estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performa nce and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s), any of which may cause Takeda's actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda's results, performance, achievements, or financial position, see "Item 3. Key Information—D. Risk Factors" in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda under takes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda's future results.
TAKEDA® Logo Disclaimer
TAKEDA®/TAKEDA Logo® (or actual logo) are registered trademarks of Takeda Pharmaceutical Company Limited.
[i] HAE, hereditary angioedema, Bork K, et al. J Allergy Clin Immunol. 2012;130(3):692-697
[ii] Bork K, et al. J Allergy Clin Immunol. 2012;130(3):692-697
[iii] Bork K, et al. J Allergy Clin Immunol. 2012;130(3):692-697
[iv] Ankur Kumar Jindal, Hereditary Angioedema: Diagnostic Algorithm and Current Treatment Concepts, (Source – Internet) https://pubmed.ncbi.nlm.nih.gov/34934714/
[v] HAE, hereditary angioedema, Bork K, et al. J Allergy Clin Immunol. 2012;130(3):692-697
[vi] Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy. Journal of Allergy and Clinical Immunology. 2010 Nov;126(5):918–25.
[vii] Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy. Journal of Allergy and Clinical Immunology. 2010 Nov;126(5):918–25.
[viii] Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clinical Immunol. 2012;130(3):692-697. (Source – Internet) https://pubmed.ncbi.nlm.nih.gov/22841766/
[ix] Aleena Banerji, Hereditary angioedema: classification, pathogenesis, and diagnosis, (Source – Internet), https://pubmed.ncbi.nlm.nih.gov/22221432/#:~:text=Although%20HAE%20is%20often%20inherited,the%20fibrinolysis%20and%20coagulation%20systems.
[x] HAE, hereditary angioedema; SD, standard deviation; UK, United Kingdom; US, United States; WPAI, Work Productivity and Impairment Questionnaire.
[xi] HAE, hereditary angioedema; SD, standard deviation; UK, United Kingdom; US, United States; WPAI, Work Productivity and Impairment Questionnaire.
Content Sources https://educratsweb.com/3800-content.htm